Jiangsu Recbio Technology Co Ltd（02179.HK）价格

Jiangsu Recbio Technology Co., Ltd. engages in the research and development of vaccines. The company is headquartered in Taizhou, Jiangsu and currently employs 507 full-time employees. The company went IPO on 2022-03-31. The firm is still in the research and development stage. The firm's vaccine pipeline includes recombinant human papillomavirus (HPV) 9-valent vaccine, novel adjuvanted recombinant HPV 9-valent vaccine, recombinant HPV bivalent (Types 16/18) vaccine, recombinant HPV bivalent (Types 6/11) vaccine, novel adjuvanted recombinant HPV quadrivalent vaccine, novel adjuvanted recombinant shingles vaccine, novel adjuvanted recombinant respiratory syncytial virus vaccine, recombinant metapneumovirus vaccine, recombinant human cytomegalovirus vaccine, recombinant bicomponent COVID-19 vaccine, recombinant hepatitis B virus vaccine, and others.